Actively Recruiting
Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia
Led by University of Bari Aldo Moro · Updated on 2025-05-30
76
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy. However, a nasal PCR-assay for MRSA has a high negative predictive value and can facilitate rapid antibiotic de-escalation, thereby avoiding unnecessary anti-MRSA treatments. The indiscriminate use of these drugs has contributed to the emergence of resistant S. aureus strains and has led to significant adverse effects, without providing any survival benefits. Additionally, it has increased hospital stays and associated costs. The proposed study aims to use this diagnostic tool to shorten empirical anti-MRSA treatment duration in pneumonia patients, focusing on reducing antimicrobial therapy days while measuring in-hospital mortality, length of stay and adverse drug event incidence.
CONDITIONS
Official Title
Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects 18 years or older
- Patients hospitalized at the Azienda Consorziale Policlinico di Bari
- Clinical diagnosis of community-acquired, hospital-acquired, or ventilator-associated pneumonia
- Prescribing physician has committed to start empirical anti-MRSA antibiotic therapy
- Enrollment within 48 hours from the start of empirical anti-MRSA therapy
You will not qualify if you...
- Febrile neutropenia or severe immunodeficiency
- Chronic airway infection such as cystic fibrosis
- Suspected extrapulmonary infection by MRSA
- Patient or legal guardian refuses to participate
- Treating physician refuses to perform antibiotic de-escalation based on nasal swab results
- Enrollment after 48 hours from the start of empirical anti-MRSA therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Università di Bari "Aldo Moro"
Bari, Italy, 70124
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here